Cancer Genetics, Inc. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Cancer Genetics, Inc. (“Cancer Genetics” or the “Company”) (NASDAQ: CGIX) with StemoniX, Inc. (“StemoniX”). Under the terms of the merger, Cancer Genetics will issue shares of common stock to the owners of StemoniX, with current holders of Cancer Genetics common stock controlling only 22% of the combined company.

The Cancer Genetics merger investigation concerns whether the Board of Cancer Genetics breached their fiduciary duties to stockholders by agreeing to enter into this transaction and whether the merger undervalues Cancer Genetics relative to StemoniX, thereby harming Cancer Genetics shareholders.